Huang, Hai-Tsang http://orcid.org/0000-0002-4244-2304
Lumpkin, Ryan J. http://orcid.org/0000-0002-2331-0998
Tsai, Ryan W.
Su, Shuyao http://orcid.org/0009-0004-4423-5415
Zhao, Xu
Xiong, Yuan http://orcid.org/0000-0002-2211-8267
Chen, James http://orcid.org/0000-0001-6039-613X
Mageed, Nada http://orcid.org/0009-0005-0046-6104
Donovan, Katherine A. http://orcid.org/0000-0002-8539-5106
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Sellers, William R. http://orcid.org/0000-0002-3539-9803
Article History
Received: 13 July 2023
Accepted: 26 February 2024
First Online: 21 March 2024
Competing interests
: W.R.S. and H.-T.H. are inventors on a filed patent describing E-STUB (PCT application publication WO/2023/235313). W.R.S. is a board or scientific advisory board (SAB) member and holds equity in Ideaya Biosciences, Civetta Therapeutics, Red Ridge Bio, Delphia Therapeutics and 2Seventy Bio. W.R.S. has consulted for Array, Astex, Epidarex Capital, Ipsen, PearlRiver Therapeutics, Merck Pharmaceuticals, Sanofi, Servier and Syndax Pharmaceuticals and receives research funding from Pfizer Pharmaceuticals, Merck Pharmaceuticals, Ideaya Biosciences, Calico, Boehringer Ingelheim, Bristol Myers Squibb, Novartis Institutes for Biomedical Research, Bayer Pharmaceuticals and Ridgeline Discovery. E.S.F. is a founder, SAB member and equity holder of Civetta Therapeutics, Lighthorse Therapeutics, Proximity Therapeutics and Neomorph (also board of directors). E.S.F. is an equity holder and SAB member for Avilar Therapeutics and Photys Therapeutics and a consultant to Novartis, Sanofi, EcoR1 Capital, Ajax Therapeutics and Deerfield. The Fischer Lab receives or has received research funding from Deerfield, Novartis, Ajax, Interline and Astellas. K.A.D. is a consultant to Kronos Bio and Neomorph. The other authors declare no competing interests.